Download PDF
Dtsch Med Wochenschr 2022; 147(16): 1068-1077
DOI: 10.1055/a-1868-9164
Übersicht

Metabolisches Syndrom und Krebsrisiko

Metabolic syndrome and cancer risk
Hans Scherübl
› Further Information
Also available at
    Permissions and Reprints

Krebs zählt zu den führenden Todesursachen beim metabolischen Syndrom (MetS). Je mehr Komponenten des metabolischen Syndroms jemand hat, desto stärker steigt das Tumorrisiko, z. B. Karzinome des Dickdarms. Bei adipösen MetS-Patienten kann die Gewichtsreduktion das Krebsrisiko senken. Dem MetS vorzubeugen und regelmäßig an Vorsorgeuntersuchungen teilzunehmen ist wichtig und verringert das Risiko, an Krebs zu erkranken und daran zu versterben.

Abstract

Cancer has become a leading cause of death among patients with metabolic syndrome (MetS). The more components of MetS a patient has, the higher his risk of cancer. MetS is causally associated with colorectal, pancreatic, gallbladder, biliary, hepatocellular, gastric, esophageal, thyroid, breast, endometrial and renal cell cancers. MetS increases cancer mortality up to 2,4-fold. Intentional long-term weight loss reduces the excess cancer risk of obese MetS-patients. Both a low-risk lifestyle and cancer screening are effective and decrease the burden of cancer.

Schlüsselworter

metabolisches Syndrom - MetS - Tumorrisiko - Prävention - Diabetes - Übergewicht - HDL

Key words

metabolic syndrome - tumor risk - prevention - diabetes - obesity - HDL


Publication History

Article published online:
15 August 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Dagenais GR, Leong DP, Rangarajan S. et al. Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. Lancet 2020; 395: 785-794
    CrossrefPubMedSearch in Google Scholar
  • 2 Lee JS, Cho SI, Park HS. Metabolic syndrome and cancer-related mortality among Korean men and women. Ann Oncol 2010; 21: 640-645
    CrossrefPubMedSearch in Google Scholar
  • 3 Gathirua-Mwangi WG, Monahan PO, Murage MJ. et al. Metabolic syndrome and total cancer mortality in the Third National Health and Nutrition Examination Survey. Cancer Causes Control 2017; 28: 127-136
    Search in Google Scholar
  • 4 Watanabe J, Kakehi E, Kotani K. et al. Metabolic syndrome is a risk factor for cancer mortality in the general Japanese population: the Jichi Medical School Cohort Study. Diabetol Metab Syndr 2019; 11: 3
    Search in Google Scholar
  • 5 López-Jiménez T, Duarte-Salles T, Plana-Ripoll O. et al. Association between metabolic syndrome and 13 types of cancer in Catalonia: A matched case-control study. PLoS One 2022; 17 (03) e0264634
    Search in Google Scholar
  • 6 Esposito K, Chiodini P, Colao A. et al. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 2012; 35: 2402-2411
    Search in Google Scholar
  • 7 Tran TT, Gunathilake M, Lee J. et al. Association between metabolic syndrome and its components and incident colorectal cancer in a prospective cohort study. Cancer 2022; 128: 1230-1241
    CrossrefPubMedSearch in Google Scholar
  • 8 Simon TG, King LY, Chong DQ. et al. Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies. Hepatology 2018; 67: 1797-1806
    CrossrefPubMedSearch in Google Scholar
  • 9 Sung H, Siegel RL, Rosenberg PS. et al. Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. Lancet Public Health 2019; 4: e137-e147
    Search in Google Scholar
  • 10 Célind J, Bygdell M, Martikainen J. et al. Childhood overweight and risk of obesity-related adult cancer in men. Cancer Commun (Lond) 2022;
    CrossrefPubMedSearch in Google Scholar
  • 11 Ulmer H, Borena W, Rapp K. et al Serum triglyceride concentrations and cancer risk in a lare cohort study in Austria. Br J Cancer 2009; 101: 1202-1206
    CrossrefPubMedSearch in Google Scholar
  • 12 Jafri H, Alsheikh-Ali AA, Karas RH. Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J Am Coll Cardiol 2010; 55: 2846-2854
    CrossrefPubMedSearch in Google Scholar
  • 13 Stocks T, Van Hemelrijck M, Manjer J. et al Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project. Hypertension 2012; 59: 802-810
    CrossrefPubMedSearch in Google Scholar
  • 14 Moore SC, Lee IM, Weiderpass E. et al. Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults. JAMA Intern Med 2016; 176: 816-825
    CrossrefPubMedSearch in Google Scholar
  • 15 Papadimitriou N, Markozannes G, Kanellopoulou A. et al. An umbrella review of the evidence associating diet and cancer risk at 11 anatomical sites. Nat Commun 2021; 12: 4579
    CrossrefPubMedSearch in Google Scholar
  • 16 Rustgi VK, Li Y, Gupta K. et al. Bariatric Surgery Reduces Cancer Risk in Adults With Nonalcoholic Fatty Liver Disease and Severe Obesity. Gastroenterology 2021; 161 (01) 171-184
    CrossrefPubMedSearch in Google Scholar
  • 17 Sjöholm K, Carlsson LMS, Svensson PA. et al. Association of Bariatric Surgery With Cancer Incidence in Patients With Obesity and Diabetes: Long-Term Results From the Swedish Obese Subjects Study. Diabetes Care 2021; 45 (02) 444-450
    CrossrefPubMedSearch in Google Scholar
  • 18 Wang L, Lin M, Yu J. et al. The Impact of Bariatric Surgery Versus Non-Surgical Treatment on Blood Pressure: Systematic Review and Meta-Analysis. Obes Surg 2021; 31: 4970-4984
    CrossrefPubMedSearch in Google Scholar
  • 19 Syn NL, Cummings DE, Wang LZ. et al. Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants. Lancet 2021; 397: 1830-1841
    CrossrefPubMedSearch in Google Scholar
  • 20 Vuik F, Nieuwenburg S, Bardou M. et al. Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut 2019; 68: 1820-1826
    CrossrefPubMedSearch in Google Scholar
  • 21 Shen X, Wang Y, Zhao R. et al. Metabolic syndrome and the risk of colorectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis 2021; 36: 2215-2225
    CrossrefPubMedSearch in Google Scholar
  • 22 O’Sullivan DE, Sutherland RL, Town S. et al. Risk Factors for Early-Onset Colorectal Cancer: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2021; 20 (06) 1229-1240
    CrossrefPubMedSearch in Google Scholar
  • 23 Milano A, Bianco MA, Buri L. et al. Metabolic syndrome is a risk factor for colorectal adenoma and cancer: a study in a White population using the harmonized criteria. Therap Adv Gastroenterol 2019; 12
    CrossrefPubMedSearch in Google Scholar
  • 24 Lu L, Koo S, McPherson S. et al. Systematic review and meta-analysis: Associations between metabolic syndrome and colorectal neoplasia outcomes. Colorectal Dis 2022;
    CrossrefPubMedSearch in Google Scholar
  • 25 Davidson KW, Barry MJ, Mangione CM. US Preventive Services Task Force. et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2021; 325: 1965-1977
    Search in Google Scholar
  • 26 Chen Y, Li X, Wu S. et al. Metabolic syndrome and the incidence of hepatocellular carcinoma: a meta-analysis of cohort studies. Onco Targets Ther 2018; 11: 6277-6285
    CrossrefPubMedSearch in Google Scholar
  • 27 McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology 2021; 73 (Suppl. 01) 4-13
    CrossrefPubMedSearch in Google Scholar
  • 28 Hajifathalian K, Tafesh Z, Rosenblatt R. et al. Effect of Statin Use on Cancer-related Mortality in Nonalcoholic Fatty Liver Disease: A Prospective United States Cohort Study. J Clin Gastroenterol 2022; 56: 173-180
    CrossrefPubMedSearch in Google Scholar
  • 29 Cunha V, Cotrim HP, Rocha R. et al. Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review. Ann Hepatol 2020; 19: 232-237
    CrossrefPubMedSearch in Google Scholar
  • 30 Chen CL, Yang HI, Yang WS. et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008; 135: 111-121
    CrossrefPubMedSearch in Google Scholar
  • 31 Ghidini M, Ramai D, Facciorusso A. et al. Metabolic disorders and the risk of cholangiocarcinoma. Expert Rev Gastroenterol Hepatol 2021; 15: 999-1007
    CrossrefPubMedSearch in Google Scholar
  • 32 Hwang KT, Han KD, Oh S. et al. Influence of Metabolic Syndrome on Risk of Breast Cancer: A Study Analyzing Nationwide Data from Korean National Health Insurance Service. Cancer Epidemiol Biomarkers Prev 2020; 29: 2038-2047
    CrossrefPubMedSearch in Google Scholar
  • 33 Penaranda EK, Shokar N, Ortiz M. Relationship between Metabolic Syndrome and History of Cervical Cancer among a US National Population. ISRN Oncol 2013; 2013: 840964
    PubMedSearch in Google Scholar
  • 34 Zhang H, Kong W, Han C. et al. Correlation of Metabolic Factors with Endometrial Atypical Hyperplasia and Endometrial Cancer: Development and Assessment of a New Predictive Nomogram. Cancer Manag Res 2021; 13: 7937-7949
    CrossrefPubMedSearch in Google Scholar
  • 35 Wang L, Du ZH, Qiao JM. et al. Association between metabolic syndrome and endometrial cancer risk: a systematic review and meta-analysis of observational studies. Aging (Albany NY) 2020; 12 (10) 9825-9839
    CrossrefPubMedSearch in Google Scholar
  • 36 Zhang Q, Chen P, Tian R. et al. Metabolic Syndrome is an Independent Risk Factor for Fuhrman Grade and TNM Stage of Renal Clear Cell Carcinoma. Int J Gen Med 2022; 15: 143-150
    CrossrefPubMedSearch in Google Scholar
  • 37 Park JH, Han K, Hong JY. et al. Changes in Metabolic Syndrome Status are Associated With Altered Risk of Pancreatic Cancer: A Nationwide Cohort Study. Gastroenterology 2022; 162: 509-520
    CrossrefPubMedSearch in Google Scholar
  • 38 Kartal E, Schmidt TSB, Molina-Montes E. et al. A faecal microbiota signature with high specificity for pancreatic cancer. Gut 2022; 71 (07) 1359-1372
    CrossrefPubMedSearch in Google Scholar
  • 39 Santos AP, Santos AC, Castro C. et al. Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors. Cancers (Basel) 2018; 10 (09) 293
    CrossrefPubMedSearch in Google Scholar
  • 40 Zhang J, Wu H, Wang R. Metabolic syndrome and esophageal cancer risk: a systematic review and meta analysis. Diabetol Metab Syndr 2021; 13 (01) 8
    CrossrefPubMedSearch in Google Scholar
  • 41 Mariani M, Sassano M, Boccia S. Metabolic syndrome and gastric cancer risk: a systematic review and meta-analysis. Eur J Cancer Prev 2021; 30 (03) 239-250
    CrossrefPubMedSearch in Google Scholar
  • 42 Jun JK, Choi KS, Lee HY. et al. Effectiveness of the Korean National Cancer Screening Program in reducing gastric cancer mortality. Gastroenterology 2017; 152: 1319-1328
    CrossrefPubMedSearch in Google Scholar
  • 43 Zhou CB, Pan SY, Jin P. et al. Fecal Signatures of Streptococcus anginosus and Streptococcus constellatus for Noninvasive Screening and Early Warning of Gastric Cancer. Gastroenterology 2022; 162 (07) 1933-1947
    CrossrefPubMedSearch in Google Scholar